Vinblastine News and Research

RSS
Vinblastine is the active ingredient in a drug used together with other drugs to treat several types of cancer, including advanced Hodgkin lymphoma and advanced testicular germinal-cell cancers. It is also being studied in the treatment of other types of cancer. Vinblastine comes from the periwinkle plant Vinca rosea Linn. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of vinca alkaloid and a type of antimitotic agent.
Increasing anti-tumor activity of compound extracted from an Amazon plant

Increasing anti-tumor activity of compound extracted from an Amazon plant

Patients with advanced Hodgkin's lymphoma may benefit from radiotherapy after chemotherapy

Patients with advanced Hodgkin's lymphoma may benefit from radiotherapy after chemotherapy

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Finding which chemotherapy regimen is associated with best outcomes for patients with bladder cancer

Finding which chemotherapy regimen is associated with best outcomes for patients with bladder cancer

OSU scientists find way to fight solid tumors using new cancer-drug delivery system

OSU scientists find way to fight solid tumors using new cancer-drug delivery system

Chemotherapy drug combination appears to increase production of eggs in women's ovaries

Chemotherapy drug combination appears to increase production of eggs in women's ovaries

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

UQDI reveals that Anisina drug can kill melanoma cells

UQDI reveals that Anisina drug can kill melanoma cells

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

TSRI scientists find new way to boost effectiveness of anticancer drugs

TSRI scientists find new way to boost effectiveness of anticancer drugs

Iridoid synthase can make powerful chemicals from catnip to vinblastine

Iridoid synthase can make powerful chemicals from catnip to vinblastine

Radiotherapy redundant in low-risk Hodgkin lymphoma treatment

Radiotherapy redundant in low-risk Hodgkin lymphoma treatment

Pediatric Hodgkin lymphoma can be treated without radiation and intensive chemotherapy

Pediatric Hodgkin lymphoma can be treated without radiation and intensive chemotherapy

Patients with muscle-invasive bladder cancer benefit from accelerated MVAC

Patients with muscle-invasive bladder cancer benefit from accelerated MVAC

Salk scientists' discovery explains how a class of chemotherapy drugs works

Salk scientists' discovery explains how a class of chemotherapy drugs works

MPC project to study how plant genes contribute to producing medicinal compounds

MPC project to study how plant genes contribute to producing medicinal compounds